NYSE · LLY
Eli Lilly and Company
$1,421.44+$47.74 (+3.47%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
Loading market information…
NASDAQ · PEAR · USD
Stock price, earnings
Quote as of Apr 18, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pear Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pear Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products. These investigational treatments span various therapeutic areas, encompassing psychiatry, neurology, and non-central nervous system conditions like gastrointestinal, oncological, and cardiovascular disorders. Founded in 2013, Pear Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2021 | Mar 31, 2021 | $0.29 | $0.00 |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,421.44+$47.74 (+3.47%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
$2.36+$0.22 (+10.28%)
Xylo Technologies Ltd.’s quoted price sits in the lower half of its reported 52-week range, 67.09% below the high.
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
$1.71+$1.71 (+100.0%)
Aptose Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.04% below the high.
$0.03$0.00 (0.0%)
Gamida Cell Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.22% below the high.
$0.24+$0.01 (+5.66%)
Hillstream BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.06% below the high.
$0.59+$0.05 (+10.0%)
Ra Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.67% below the high.
$0.03-$0.02 (-31.78%)
Gritstone bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.98% below the high.
